All In Biotech

Drug Trial Radar · NCT06619509

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Actual

Start

Dec 30, 2024

Primary completion

Dec 30, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.

Conditions

  • Solid Tumours

Interventions

  • BrigimadlinDrug

    Brigimadlin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment periodTime frame: up to 9 years.

Locations

50 sites in 20 countries. Site status is shown where the registry gives one.

  • Precision NextGen Oncology

    Beverly Hills, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic Cancer Center

    Jacksonville, Florida

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Cancer Specialists-Omaha-69066

    Omaha, Nebraska

  • Northwell Health

    Lake Success, New York

  • West Cancer Center & Research Institute

    Germantown, Tennessee

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists Cancer Center

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Sanatorio Finochietto

    CABA, Argentina

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Arthur J. E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China

  • University Hospital Olomouc

    Olomouc, Czechia

  • Copenhagen University Hospital, Rigshospitalet

    København Ø, Denmark

  • CTR Leon Berard

    Lyon, France

  • CTR Eugène Marquis

    Rennes, France

  • Helios Klinikum Berlin-Buch

    Berlin, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Clinexpert Gyongyos

    Gyöngyös, Hungary

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Istituto Oncologico Veneto IRCCS

    Padova, Italy

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • Kanagawa Cancer Center

    Kanagawa, Yokohama, Japan

  • Tohoku University Hospital

    Miyagi, Sendai, Japan

  • Okayama University Hospital

    Okayama, Okayama, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • Oslo Universitetssykehus HF, Radiumhospitalet

    Oslo, Norway

  • Oncology Center-Maria Sklodowska-Curie Institute

    Warsaw, Poland

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.